Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Data from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S1 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S10 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S12 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S13 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S13 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S14 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S14 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S15 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S15 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S16 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S16 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S2 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S2 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S4 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S5 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S5 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S6 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Figure S6 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

TET CpG sequence context specific DNA demethylation shapes progression of IDH-mutant gliomas

Table S1 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S2 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen

Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen